ConductScience.org, home

Paper36938364

A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition.

Thuru X and 3 others. Biomed Hub, 2023. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition. Papers, record 36938364. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36938364

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition.
PubMed
Journal
Biomed Hub
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.7
iCite
Revised in PubMed
2023-03-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Thuru XXavier
2Magnez RRomain
3Vergoten GGérard
4Bailly CChristian

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134103659PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.Commun Biol2021https://conductscience.org/library/papers/34103659PubMed
227083005Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).Oncotarget2016https://conductscience.org/library/papers/27083005PubMed
332352272mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).ACS Chem Biol2020https://conductscience.org/library/papers/32352272PubMed
434769226PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action.Int J Mol Sci2021https://conductscience.org/library/papers/34769226PubMed
532871472N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.Comput Biol Chem2020https://conductscience.org/library/papers/32871472PubMed
635132224Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.Nat Rev Clin Oncol2022https://conductscience.org/library/papers/35132224PubMed
731586036Crlz-1 Controls Germinal Center Reaction by Relaying a Wnt Signal to the Bcl-6 Expression in Centroblasts during Humoral Immune Responses.J Immunol2019https://conductscience.org/library/papers/31586036PubMed
835629327Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy.Life (Basel)2022https://conductscience.org/library/papers/35629327PubMed
927294323Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation.Nat Chem Biol2016https://conductscience.org/library/papers/27294323PubMed
1034381360Potential Role of Traditional Chinese Medicines by Wnt/β-Catenin Pathway Compared With Targeted Small Molecules in Colorectal Cancer Therapy.Front Pharmacol2021https://conductscience.org/library/papers/34381360PubMed
1130459318A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.Exp Mol Med2018https://conductscience.org/library/papers/30459318PubMed
1231972166Protein homodimer sequestration with small molecules: Focus on PD-L1.Biochem Pharmacol2020https://conductscience.org/library/papers/31972166PubMed
1331839668Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.Biomed Res2019https://conductscience.org/library/papers/31839668PubMed
1435684392Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.Molecules2022https://conductscience.org/library/papers/35684392PubMed
1527470214Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer.BMB Rep2016https://conductscience.org/library/papers/27470214PubMed
1628768162Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.Structure2017https://conductscience.org/library/papers/28768162PubMed
1735630791Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents.Molecules2022https://conductscience.org/library/papers/35630791PubMed
1835352805Targeting β-catenin in acute myeloid leukaemia: past, present, and future perspectives.Biosci Rep2022https://conductscience.org/library/papers/35352805PubMed
1930965636A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS.Cancers (Basel)2019https://conductscience.org/library/papers/30965636PubMed
2032445869Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer.Biochem Pharmacol2020https://conductscience.org/library/papers/32445869PubMed

See all 49 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
40206274Unraveling the Role of the Wnt Pathway in Hepatocellular Carcinoma: From Molecular Mechanisms to Therapeutic Implications.J Clin Transl Hepatol2025https://conductscience.org/library/papers/40206274PubMed
39038454RNA therapeutics targeting PD-L1 is a promising immune-activation strategy against difficult-to-treat cancers.Mol Ther2024https://conductscience.org/library/papers/39038454PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36938364

GET https://conductscience.org/api/papers/v1/36938364/references?page=2